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Introduction
Hodgkin lymphoma (HL) is a malignant lymphoma of B-cell origin. 1 The malignant cells, known as Reed-Sternberg (RS) cells, represent less than 2% of the tumor mass, the remainder composed of a mix of reactive inflammatory cells attracted by the RS cells. Patients usually present with lymphadenopathy, organomegaly, and constitutional symptoms. 2 Chemotherapy with or without radiation cures most patients. However, some patients develop recurrent disease and are given sequential chemotherapeutic or immunotherapeutic agents to control tumor growth. 3 Unfortunately, cumulative toxicities and progressive resistance limit benefits. Safer therapies with novel mechanisms of action are needed for patients with relapsed HL.
Phosphatidylinositol 3-kinases (PI3Ks) are enzymes that mediate signals from cell surface receptors. The 4 class I PI3K isozymes (PI3K␣, PI3K␤, PI3K␥, and PI3K␦) regulate a variety of cellular functions through the production of phosphatidylinositol-3,4,5-triphosphate. 4 Generation of phosphatidylinositol-3,4,5-triphosphate activates the downstream serine/threonine kinase, Akt, and the mammalian target of rapamycin (mTOR), both of which have positive effects on cell survival, proliferation, growth, and metabolism. 5, 6 Dysregulation of the PI3K/Akt/mTOR pathway is important in the etiology of human malignancies. 5, 7 Of the several PI3K isoforms, PI3K␦ has been shown to play a pivotal role in B-cell signaling in response to chemokines and cytokines. [8] [9] [10] Past studies have indicated a role for the PI3K/Akt/mTOR pathway in the pathogenesis of HL 11, 12 and have suggested that PI3K might constitute an important therapeutic target in this disease. GS-1101 is a novel, oral, PI3K␦-specific inhibitor that has shown activity in other types of B-cell cancers. 8, 9, 13, 14 We now characterize the activity of GS-1101 in cellular models of HL, providing translational support for PI3K␦ inhibition as a novel strategy for the treatment of HL.
Methods

Immunoblotting and ELISA analysis
Whole-cell lysates were analyzed on 10% polyacrylamide gels, transferred to polyvinylidene difluoride (PVDF), blocked, probed with antibodies, and detected using the Odessy from LiCor as previously described. 15 The effect of GS-1101 on CCL5 secretion was measured as previously described. 8 After 24 hours, supernatants were harvested and assayed for CCL5 by quantitative ELISA according to the manufacturer's instructions (Quantikine, R&D Systems).
Cell viability and apoptosis
Cell viability was assessed using Cell Titer Aqueous One Solution Cell Proliferation Assay reagent (Promega) following the manufacturer's protocol. For cell-cycle analysis, cells were permeabilized, stained with propidium iodide, and subjected to FACS evaluation of labeled DNA. Apoptosis was measured by annexin V-FITC/7-amino-actinomycin D (7-AAD) labeling followed by fluorescence flow cytometry as previously described. 9 
Immunohistochemistry
Immunohistochemical methods to detect expression of the four PI3K isoforms were performed using routinely processed tissue microarray specimens.
These tissue microarrays were constructed with triplicate cores from selected areas of 103 formalin-fixed, paraffin-embedded classic HL samples. The tissue sections were incubated for 60 or 90 minutes at room temperature with antibodies specific for PI3K␣ (dilution 1:400; Cell Signaling), ␤ (3 g/mL; Abcam), and ␥ (1:100) and ␦ (1:100; Santa Cruz Biotechnology). Protein expression levels were scored as negative, weakly positive, or strongly positive, depending on the staining signal intensity. Sections of lung adenocarcinoma were used as a positive control for PI3K␣, ␤, and ␥, and sections of a case of diffuse large B-cell lymphoma were used as positive control for the ␦ isoform.
Results and discussion
PI3K isoform expression and pathway activation in HL cell lines and primary patient samples
We first investigated the level of expression of each PI3K isoform in 5 HL cell lines. In all cases, we detected high levels of PI3K␦. The majority of the cells also expressed PI3K␣ and PI3K␤, but at lower levels ( Figure 1A ). PI3K␥ was only detected in one cell line (L428). Immunohistochemical analysis in HL tumor samples revealed expression of PI3K␣ and PI3K␦ in 97.2% and 80.6% of the cases, respectively ( Figure 1B ; supplemental Figure 1 , available on the Blood Web site; see the Supplemental Materials link at the top of the online article). Staining for the PI3K␤ and ␥ isoforms was found to be weak or absent in most HL samples tested ( Figure 1B ; supplemental Figure 1 ). These data demonstrate that PI3K␦ is highly expressed in HL cell lines and in tumor samples.
Previous studies have reported high constitutive levels of the active, phosphorylated form of Akt (pAkt) in RS cells in primary lymph node sections of HL. 11, 12 To evaluate constitutive PI3K pathway activation, we screened HL-derived cell lines for pAkt S473 . We found that, in all HL cell lines tested, pAkt S473 was readily detected. To determine whether Akt phosphorylation was dependent on PI3K␦, unstimulated cell lines were incubated with GS-1101. GS-1101 induced a dose-dependent reduction in pAkt. These findings confirm a functional role for the PI3K␦ isoform in HL cell lines ( Figure 1C) .
Evaluation of PI3K␦ function in HL cocultures
Inflammatory cells are composed of a large portion of HL tumors, and the tumor microenvironment appears to be essential for RS cell survival and growth. 16 In models of non-Hodgkin lymphoma, the human bone marrow stromal cell line, HS-5, promotes malignant B-cell growth and protects lymphoma cells from cytotoxic drugs. 17, 18 To examine microenvironmental influences on PI3K/Akt signaling, and ␦ were the isoforms more frequently expressed in tumor samples; they were detected in 97.2% and 80.6% of the cases, respectively. Strong expression of PI3K␣ and ␦ was detected in 37.5% and 26.4% of cases, respectively. Protein expression was scored as Ϫ, ϩ, or ϩϩ depending on the staining signal intensity. Expression of each isoform in the Hodgkin RS cells was compared with that seen in positive control; if higher or equal, then expression of each p110 isoform was considered ϩϩ; and if lower, then expression was considered ϩ (supplemental Figure 1 we cocultured HL cell lines with HS-5 cells. The presence of the HS-5 cells increased expression of pAkt in L1236, L428, and L591 cells. To determine the role of PI3K␦ in this expression, we established L1236, L428, and L591 cells in coculture with HS-5 cells for 24 hours and then treated with GS-1101. In this setting, we observed a significant decrease in the level of stroma-induced pAkt ( Figure 1D ).
Elevated concentrations of circulating chemokines have been shown to contribute to RS cell proliferation and survival, and to the formation and maintenance of the tumor microenvironment. 16 CCL5, a chemokine produced by RS cells, has both a direct effect on RS cell survival and on microenvironment formation. 19 We measured levels of CCL5 in cell supernatants 24 hours after initiation of GS-1101 treatment. The L1236 and L591 cell lines produced CCL5, showing supernatant concentrations of 1500 pg/mL and 786 pg/mL, respectively. Incubation of L1236 and L591 cells with GS-1101 significantly reduced the detectable CCL5 levels (P Ͻ .05, n ϭ 5), as displayed in Figure 2A , suggesting that CCL5 secretion can be PI3K␦ dependent. Interestingly, coculture with HS-5 cells induced the HL cells to secrete high concentrations CCL5 into the supernatants. Treatment with GS-1101 was able to down-regulate the secretion of CCL5 in stromal cocultures ( Figure  2A) , indicating that the induction of CCL5 secretion in HL cocultures may be reliant on PI3K␦.
GS-1101 induces cell cycle arrest and apoptosis in RS cell lines
To determine whether inhibition of PI3K␦ by GS-1101 affects the viability of HL cell lines, L1236 and L591 cells were treated with GS-1101 and cell-cycle analysis was performed. Twenty-four hours of GS-1101 treatment resulted in an accumulation of cells in G 1 and a decrease in the S-phase population ( Figure 2B ). After 48 hours of GS-1101 exposure, a 2.5-fold increase in annexin V-positive cells was observed, indicating a significant (P Ͻ .05) increase in apoptosis ( Figure 2B ). BLOOD, 23 FEBRUARY 2012 ⅐ VOLUME 119, NUMBER 8 For personal use only. on April 8, 2017 . by guest www.bloodjournal.org From mTOR inhibitors have shown antitumor activity in non-Hodgkin lymphoma and HL. [20] [21] [22] However, these drugs may not optimally inhibit the PI3K/Akt/mTOR pathway because they can increase pAkt by a feedback loop, thus suggesting that combination therapy may offer advantages. 23 We assessed whether GS-1101 could enhance the antitumor effects of mTOR inhibition with everolimus (RAD001) in L1236 and L591 cell lines. After treatment with GS-1101 in the presence or absence of everolimus for 48 hours, the combination showed greater dose-dependent inhibition of cell viability compared with each agent alone ( Figure 2C ; supplemental Figure 2 ). In addition, GS-1101 increased the number of everolimusinduced annexin V-positive cells, indicating increased apoptosis ( Figure 2C ).
In conclusion, our results confirm the potential importance of the PI3K/Akt/mTOR pathway in HL growth and survival and document that specific inhibition of PI3K␦ with GS-1101 can disrupt pathway activation. Our data suggest that PI3K␦ inhibition can overcome pro-survival signals from the microenvironment that maintain HL cells and reduce levels of CCL5, a chemokine with autocrine effects on RS proliferation and paracrine actions on inflammatory cell recruitment. Collectively, the data suggest a critical role for PI3K␦ in maintaining HL tumor lesions and provide strong preclinical rationale for clinical evaluation of GS-1101 in patients with HL.
